不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性 DLBCL 的耐药机制及新型靶向药物与治疗
英文原题：Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL.
查看英文原题
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤（NHL）。约30%–40%的DLBCL患者对标准R-CHOP方案耐药或在缓解后复发。目前认为，耐药是DLBCL复发和难治（R/R DLBCL）的主要原因。随着对DLBCL生物学、肿瘤微环境和表观遗传学认识加深，一些新型治疗和药物已用于R/R DLBCL，包括分子及信号通路靶向治疗、嵌合抗原受体（CAR）T细胞疗法、免疫检查点抑制剂、抗体药物偶联物以及tafasitamab。本文综述DLBCL的耐药机制及新型靶向药物和疗法。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory of DLBCL (R/R DLBCL).
With the increased understanding of DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab have been used for R/R DLBCL. This article will review the drug resistance mechanism and novel targeted drugs and therapies of DLBCL.
论文信息
- 作者
- Zhang J、Gu Y、Chen B
- 单位
- Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China.China
- 文献类型
- 综述
- 期刊
- Cancer management and research2023
- 原文标识
- PubMed 36873252 · DOI 10.2147/CMAR.S400013
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →